Development and validation ofreversed-phase-HPLC method forsimultaneous quantification of fulvestrantand disulfiram in liposomes: supplementary materials

This study aims to develop and validate an HPLC technique for the determination of fulvestrant anddisulfiram in liposomes. Encapsulation of both drugs into liposomes may improve their anticancerpotential. Validation was performed following the International Conference on Harmonization guidelinesfor specificity, linearity, limit of detection, limit of quantification, precision, accuracy and robustness.Method specificity displayed no interference and linearity over 25–200 and 12.5–100 μg/ ml forfulvestrant and disulfiram, respectively. Precision and accuracy exhibited a low relative standard deviation(<1.70%) and appropriate recovery. The validated method could be designated as a proper methodfor the simultaneous determination of fulvestrant and disulfiram in liposomes. The liposomes displayed148.5 ± 5.1 nm size. The encapsulation efficiencies were 73.52 and 50.50% for fulvestrant and disulfiram,respectively.